These 2 Cannabis Stocks Just Dropped in Price, but Are They a Buy?

Cronos Group Inc. (TSX:CRON)(NYSE:CRON) and Aphria Inc. (TSX:APHA)(NYSE:APHA) both just dropped in share price after a big week, but are they a buy?

| More on:
Man considering whether to sell or buy

Image source: Getty Images.

It was a great week for cannabis stocks. Or at least, it would have been, but for Friday.

For some reason, investors took the opportunity to take their gains and go on a lot of cannabis stocks. Canopy Growth Corp.Aurora Cannabis Inc., and Hexo Corp. were just some of the stocks seeing losses that brought them back to Monday’s share prices.

Two other cannabis stocks that saw a loss were Cronos Group Inc. (TSX:CRON)(NYSE:CRON) and Aphria Inc. (TSX:APHA)(NYSE:APHA). These names have remained among many of the heavy hitters since legalization, but before you go ahead and buy more of the above stocks mentioned at these lower prices, let’s look at whether it’d be such a great idea.

Cronos

It’s not hard to find overvalued cannabis stocks, but when it comes to Cronos, it’s pretty much a miracle that its share price has remained so high. This could be due to the recent closure of the deal between Cronos and Altria Group. The cigarette giant invested $1.8 billion in the cannabis company, in return getting a 45% stake in Cronos. This has given Cronos international reach overnight.

But international reach doesn’t mean much if you don’t have the product, and right now, Cronos only has the capacity to produce 120,000 kilograms. Hopefully it uses the Altria cash to expand, but it’s all “coulds” and “shoulds” until there are any real announcements.

So while the deal is great for Cronos, and will be for investors in the far-off future, right now it’s a waiting game. The stock is trading at about $26 per share at writing, but analysts are putting its fair value closer to $18. Ouch. So if it were me, I’d wait until the share price reaches that range before buying.

Aphria

Another stock fuelled by recent news is Aphria Inc. This cannabis company recently received a full production license from Health Canada to expand its Aphria One production facility. The news means that Aphria can seriously ramp up production in the 800,000 square-foot facility to produce 115,000 kilograms per year.

While that’s good news, it hasn’t helped the recent drama surrounding Aphria. The company was accused by short sellers of purchasing shell companies in Latin America that proved to be “largely worthless,” selling those companies almost immediately at insane prices to pocket the cash.

Of course the company denies these claims, and a report has since been released stating that Aphria paid a reasonable amount for the Latin American cannabis companies. But it definitely shook the stock for months.

Now the company is seeing a rebound, but analysts are still placing the current share price at pretty near fair value. In this case, it’s a gamble to purchase it right now. While the news of a production license means Aphria could be back in the spot of lowest cost per gram of cannabis producer, it still needs to prove its worth to investors.

Bottom line

Both Cronos and Aphria have a ways to go to show investors that these companies deserve their money. At the end of this wild ride of a week, I’d be more interested in a few steadier options before heading down a potentially turbulent path like Cronos or Aphria.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has no position in any of the stocks mentioned.

More on Cannabis Stocks

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Are Cannabis Stocks Still a Thing in 2023?

The whole question of whether cannabis stocks are still relevant in 2023 is an interesting one. Here's my take on…

Read more »

A cannabis plant grows.
Cannabis Stocks

Why Canopy Growth Stock Fell 72% Last Year

Canopy Growth stock is a beaten-up cannabis giant that is trading at a discount compared to historical multiples. But is…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is SNDL Stock a Buy in January 2023?

SNDL is among the worst-performing cannabis stocks in the last three years. But is SNDL stock a buy right now?

Read more »

a person watches a downward arrow crash through the floor
Cannabis Stocks

Why Tilray Stock Fell Almost 60% in 2022

Tilray is a Canadian cannabis stock that is down 93% from all-time highs. Let's see if TLRY stock is a…

Read more »